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Association of Left Atrial Volume With Mortality Among ESRD Patients
With Left Ventricular Hypertrophy Referred for Kidney Transplantation
Rajan K. Patel, MBChB,1,2 Alan G. M. Jardine, BSc,1 Patrick B. Mark, PhD,1,2
Anthony F. Cunningham, BSc,3 Tracey Steedman, BSc,3 Joanna R. Powell, MBChB,1,2
Emily P. McQuarrie, MBChB,1,2 Kathryn K. Stevens, MBChB,1,2 Henry J. Dargie, MD,3 and
Alan G. Jardine, MD1,2
Background: Left ventricular hypertrophy (LVH) is common in patients with end-stage renal disease
(ESRD) and an independent risk factor for premature cardiovascular death. Left atrial volume (LAV),
measured using echocardiography, predicts death in patients with ESRD. Cardiovascular magnetic
resonance (CMR) imaging is a volume-independent method of accurately assessing cardiac structure
and function in patients with ESRD.
Study Design: Single-center prospective observational study to assess the determinants of all-cause
mortality, particularly LAV, in a cohort of ESRD patients with LVH, defined using CMR imaging.
Setting & Participants: 201 consecutive ESRD patients with LVH (72.1% men; mean age, 51.6 
11.7 years) who had undergone pretransplant cardiovascular assessment were identified using CMR
imaging between 2002-2008. LVH was defined as left ventricular mass index 84.1 g/m2 (men) or
74.6 g/m2 (women) based on published normal left ventricle dimensions for CMR imaging. Maximal
LAV was calculated using the biplane area-length method at the end of left ventricle systole and
corrected for body surface area.
Predictors: CMR abnormalities, including LAV.
Outcome: All-cause mortality.
Results: 54 patients died (11 after transplant) during a median follow-up of 3.62 years. Median LAV was
30.4 mL/m2 (interquartile range, 26.2-58.1). Patients were grouped into high (median or higher) or low (less
than median) LAV. There were no significant differences in heart rate and mitral valve Doppler early to late
atrial peak velocity ratio. Increased LAV was associated with higher mortality. Kaplan-Meier survival analysis
showed poorer survival in patients with higher LAV (log rank P 0.01). High LAV and left ventricular systolic
dysfunction conferred similar risk and were independent predictors of death using multivariate analysis.
Limitations: Only patients undergoing pretransplant cardiac assessment are included. Limited
assessment of left ventricular diastolic function.
Conclusions: Higher LAV and left ventricular systolic dysfunction are independent predictors of
death in ESRD patients with LVH.
Am J Kidney Dis 55:1088-1096. © 2010 by the National Kidney Foundation, Inc.
INDEX WORDS: End-stage renal disease; left ventricular hypertrophy; left atrial volume; cardiovascular
magnetic resonance imaging (MRI).p
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hatients with end-stage renal disease (ESRD)
have an increased risk of premature cardio-
ascular disease.1 Echocardiography has identi-
ed abnormalities in left ventricular structure and
unction—left ventricular hypertrophy (LVH), left
entricular systolic dysfunction (LVSD), and left
entricular dilation—that independently confer a
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ave been termed “uremic cardiomyopathy.”2,3
LVH is present in approximately 67% of patients
ith ESRD4 and is the most common manifesta-
ion of uremic cardiomyopathy. Moreover, it is an
ndependent risk factor for sudden cardiac death,
eart failure, and cardiac arrhythmias in both the
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Left Atrial Volume in ESRD Patients With LVH 1089eneral population and patients receiving hemodi-
lysis.3,5 Although common, the presence of LVH
lone has a variable prognosis. Furthermore, rever-
al of LVH in patients with ESRD has proven
ifficult,6,7 and attempts have been made to iden-
ify additional abnormalities that predict death and
re amenable to intervention.
Previous studies measuring left ventricular
ass index (LVMi: defined as left ventricular
ass corrected for body surface area [BSA]) in
atients with ESRD have used echocardiogra-
hy. However, estimation of LVMi is inaccurate
ecause of changes in intravascular volumes
uring the inter- and intra-dialytic period and
uring dialysis and geometric assumptions that
ely on intraventricular diameter to calculate
VMi using conventional echocardiography.8
ardiovascular magnetic resonance (CMR) imag-
ng provides detailed volume-independent mea-
urement of cardiac structure and is considered
he most accurate method for assessing ventricu-
ar dimensions in patients, including those with
tage 5 chronic kidney disease.9,10
Left atrial dilation (corrected for BSA or height)
easured using echocardiography is an indepen-
ent predictor of mortality in the general popula-
ion, and in patients with hypertension and
SRD.11,12 Causes of increased left atrial volume
LAV) in patients with ESRD include mitral valve
isease, fluid overload, and impaired left ventricu-
ar diastolic relaxation and filling.13 LAV can be
eliably and reproducibly measured using echocar-
iography and CMR imaging using the biplane
rea-length method.14,15 To this end, we postulated
hat increased LAV conferred poorer prognosis in
SRD patients with LVH. The aim of this study
as to identify the prognostic effect of cardiac
bnormalities, particularly increased LAV, in a co-
ort of ESRD patients with LVH identified using
MR imaging.
METHODS
tudyDesign
This was a single-center prospective observational study
o assess the determinants of all-cause mortality, particularly
AV, in a cohort of patients with ESRD with LVH defined
sing CMR.
etting
The Renal Transplant Unit at the Western Infirmary,
lasgow, provides transplant services to a population of 2.8 illion people in the West of Scotland.16 The transplant
aiting list has 300 patients at any time; approximately 120
ew patients are waitlisted and approximately 80 adult
ransplants are performed annually.
articipants
Since 2002,17 we have used CMR imaging as part of the
tandard assessment of patients who are referred for cardio-
ascular assessment before their inclusion on the kidney
ransplant waiting list. These patients were referred for
retransplant assessment because of advancing age or past/
urrent history of cardiovascular disease.
All patients receiving maintenance hemodialysis therapy
rom our unit were studied on a nondialysis day with the aim
o perform all investigations at the individuals’ “dry weight.”
nly patients with evidence of LVH on CMR imaging were
ntered into the study. To ensure that only nonvalvular
auses of left atrial dilation were assessed, patients with mild
o severe mitral valve disease on echocardiography, based on
merican Society of Echocardiography guidelines,18 were
xcluded from the study. In addition, all patients were in
inus cardiac rhythm at the time of scanning.
ariables
All-cause mortality was the principle outcome in this
tudy. To characterize factors associated with death, demo-
raphic information, past clinical history (at time of CMR
canning), and CMR measurements were recorded.
MRTechnique andAnalysis
Non–gadolinium-enhanced CMR imaging was performed
sing a 1.5-Tesla magnetic resonance imaging scanner (So-
ata; Siemens Medical, www.medical.siemens.com) to as-
ess LVM and function.9,10 Scans were performed on the
ay after their hemodialysis session. A fast imaging with
teady-state precession (true FISP) sequence was used to
cquire cine images in long-axis planes (vertical long axis,
orizontal long axis, and left ventricular outflow tract)
ollowed by sequential short-axis left ventricular cine loops
8-mm slice thickness, 2-mm gap between slices) from the
trioventricular ring to the apex. Imaging parameters, which
ere standardized for all participants, included the follow-
ng values: repetition time, 3.14 ms; echo time, 1.6 ms; flip
ngle, 60°; voxel size, 2.2  1.3  8.0 mm; and field of
iew, 340 mm.
ssessment of LVMandLAVUsingCMR Imaging
LVM and LAV were analyzed by 2 observers (R.K.P. and
.G.M.J.) blinded to patient clinical characteristics. LVM
as measured from short-axis cine loops using manual
racing of epicardial and endocardial end-systolic and end-
iastolic contours, calculated using analysis software (Ar-
us; Siemens Medical), and indexed for BSA (thus provid-
ng LVMi). According to established normal values,19 LVH
as defined as LVMi 84.1 g/m2 (male) or 76.4 g/m2
female). LVSD was defined as left ventricular ejection
raction 55%, and left ventricular dilation was defined as
nd-diastolic volume (EDV)/BSA111.7 mL/m2 (male) or
99.3 mL/m2 (female) or end-systolic volume (ESV)/BSA
92.8 mL (male) or70.3 mL (female).
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Patel et al1090The biplane area-length method for ellipsoid bodies was
sed to measure LAV.14 Horizontal and vertical long-axis
ine images were used to obtain images of the left atrium at
aximal filling. Atrial lengths and areas were measured
rom both views, and LAV was calculated. LAV was cor-
ected for BSA (LAV/BSA). Left atrial appendages were
ncluded in these measurements.
itral Valve InﬂowDoppler VelocityMeasurement
Echocardiography was performed by an experienced echo-
ardiographer (A.F.C.) using an Acuson Sequoia C512 ma-
hine (Siemens Medical). Diastolic function was assessed
sing pulsed-wave Doppler20,21 from apical 4-chamber views
o measure the ratio of early (E) to late (A) mitral inflow
eak flow velocity (E:A ratio).
tatistical Analysis
Data are described as mean  standard deviation for
ormally distributed data) or median and interquartile range
IQR) for non-normal data. Survival data including survival
ime (mean SD) are shown as Kaplan-Meier graphs (with
tatistical comparison using log-rank test). These data were
lso analyzed using Cox multivariate survival analysis to
ssess the influence of multiple clinical and cardiac variables
n outcome. Variables identified as significantly influential
n outcome by univariate analysis were entered into a
ackward stepwise regression model. All analyses were
erformed using SPSS, version 15.0 (SPSS Inc, www.spss.
om).
RESULTS
articipants andClinical Parameters
From 312 patients with ESRD assessed for
idney transplantation17 between 2002 and 2008,
e identified 201 patients with LVH. Median
ollow-up was 3.62 years (IQR, 1.2-5.2) and
ransplant-censored follow-up was 1.69 years
IQR, 1.0-3.9). Mean age of patients was 51.6
1.8 years and 72.1% were men. The first col-
mn in Table 1 lists renal replacement therapy
ode, medical history, and cardiac drug history
f the cohort.
Seventy-one patients received a kidney trans-
lant during the study period. There were 54
26.9%) deaths during a 6.65-year follow-up
eriod. Eleven deaths occurred after kidney trans-
lantation. Overall survival at 12, 24, 36, 48, and
0 months was 92%, 87%, 79%, 77%, and 74%,
espectively. Median LAV/BSA was 30.4 mL/
2
. The distribution of LAV/BSA for this cohort
s shown in Fig 1. There was no significant
orrelation between LVMi and LAV/BSA (r 
.03; P 0.7).
To identify determinants and consequences ofncreased LAV, we divided patients into high dAV (LAV/BSA equal to or higher than median;
 100) or low LAV (LAV/BSA less than
edian value; n 101; Table 1). High LAV was
ignificantly associated with treatment with st-
tins. Low LAV was significantly associated with
ale sex. There was no significant difference in
ge, number of patients who underwent kidney
ransplantation, BSA, and renal replacement type
r duration between the high- and low-LAV
roups. Furthermore, there was no significant
ifference in number of patients with diabetes
ellitus, smoking history, and cardiovascular
edical history (namely ischemic heart disease,
hronic heart failure, cerebrovascular and periph-
ral vascular diseases). On comparison of car-
iac medications, there were no other significant
ifferences between the low- and high-LAV
roups.
ardiac Parameters
Examining the entire cohort (Table 2), mean
eart rate during CMR imaging was 77  26
eats/min. Mean ejection fraction was 63.1% 
4.4%, LVMi was 117.3  31.1 g/m2, EDV/
SA was 86.3  31.4 mL/m2, and ESV/BSA
as 34.1  25.3 mL/m2. Fifty (24.9%) patients
ad LVSD and 49 (24.4%) had left ventricular
ilation. Doppler mitral valve inflow velocity
easurement showed a mean peak E wave veloc-
ty of 0.74  0.2 cm/s, mean peak A wave of
.75 0.2 cm/s, and E:A ratio of 1.04 0.5.
We also compared structural CMR imaging
nd mitral valve echocardiography Doppler re-
ults between the low- and high-LAV groups.
here were no significant differences between
eart rate during CMR imaging, ejection frac-
ion, left ventricular myocardial mass, EDV/
SA, ESV/BSA, and number of patients with
VSD or left ventricular dilation between groups.
s a basic marker of diastolic function, Doppler
itral valve inflow velocity measurement showed
o difference in E:A ratios between the low- and
igh-LAV groups.
ardiac Structure andOutcome
We initially examined the effect of left atrial
nd ventricular abnormalities on patient survival.
ivided into quartiles, increasing LAV was sig-
ificantly associated with higher mortality: quar-
ile (Q)1, 5 (10.0%) deaths; Q2, 13 (26.0%)
eaths; Q3, 17 (34.0%) deaths; and Q4, 19
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Left Atrial Volume in ESRD Patients With LVH 1091Table 1. Clinical Information for the Entire Cohort and by Low or High LAV/BSA
Variable
Total
(N  201)
Low LAV/BSA
(n  101)
High LAV/BSA
(n  100) P
idney transplants 71 (35.3) 40 (39.6) 31 (31) 0.2
ge (y) 51.6  11.8 50.4  12.6 52.8  10.9 0.1
en 145 (72.1) 82 (81.2) 63 (63) 0.004
SA (m2) 1.76  0.2 1.77  0.2 1.75  0.2 0.8
AV (mL) 56.3  9.7 50.4  6.8 62.3  8.4 0.001
BP (mm Hg) 136.9  24.6 135.6  26.2 138.4  22.8 0.5
BP (mm Hg) 80.9  12.9 82.2  13.5 79.3  12.1 0.2
RT time (HD and PD only) (y) 1.7  4.3 1.5  4.3 1.9  4.4 0.5
RT type
HD 108 (53.7) 56 (55.4) 52 (52)
PD 52 (25.9) 23 (22.8) 29 (29) 0.6
Predialysis 41 (20.4) 22 (21.8) 19 (19)
iabetes mellitus 121 (60.2) 61 (60.4) 60 (60) 0.9
schemic heart disease 54 (26.9) 24 (23.8) 30 (30) 0.4
eart failure 12 (6.0) 6 (5.9) 6 (6) 0.9
erebrovascular disease 12 (6.0) 6 (5.9) 6 (6) 0.9
eripheral vascular disease 16 (8.0) 6 (5.9) 10 (10) 0.3
moking
Never 107 (53.2) 56 (55.4) 51 (51) 0.5
Current/ex 94 (26.9) 45 (22.8) 49 (31)
PO receptor agonist 151 (75.1) 72 (71.2) 79 (79) 0.1
emoglobin (g/dL) 11.5  1.7 11.5  1.7 11.3  1.5 0.2
-Adrenoceptor blocker 87 (43.3) 45 (44.6) 42 (42) 0.8
spirin 83 (41.3) 38 (37.6) 45 (45) 0.2
arfarin 7 (3.5) 4 (4.0) 3 (3) 0.7
CEi/ARB 54 (26.9) 28 (27.7) 26 (26) 0.9
iuretic 60 (29.6) 31 (30.7) 29 (29) 0.9
alcium channel blocker 58 (28.9) 33 (32.7) 25 (25) 0.3
-Adrenoceptor blocker 21 (10.4) 13 (12.9) 8 (8) 0.3
tatin 83 (41.3) 35 (34.7) 48 (48) 0.05
Note: Values expressed as mean  standard deviation and number (percentage). The low-LAV/BSA group includes
ndividuals with LAV/BSA less than the median value; the high-LAV/BSA group includes individuals with LAV/BSA equal to
he median value or greater. Tests of significance are t test and 2.
Abbreviations and definitions: ACEi/ARB, angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker; BSA,
ody surface area; DBP, diastolic blood pressure; EPO, erythropoietin; HD, hemodialysis; LAV, left atrial volume; LAV/BSA,
eft atrial volume corrected for body surface area; PD, peritoneal dialysis; RRT, renal replacement therapy; SBP, systolic
lood pressure.
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Patel et al109237.3%) deaths; P 0.01. Furthermore, increas-
ng LAV was associated significantly with poorer
rognosis (Fig 2A: P 0.01).
Similarly, LVSD was associated with a signifi-
ant reduction in mean survival time (Fig 2B:
 0.02). Left ventricular dilation was associ-
ted with a non-significant decrease in patient
urvival (no left ventricular dilation, 5.2  1.9
ears vs left ventricular dilation, 4.7 3.7 years;
 0.2).
urvival Analyses
Table 3 lists univariate and multivariate Cox
urvival analyses for patient clinical and cardiac
Figure 1. Frequency distribution of left atrial volume
orrected for body surface area (LAV/BSA).
Table 2. Cardiac Information for En
Variable
Total
(N  201)
eart rate (beats/min) 76.8  26.1
jection fraction (%) 63.1  14.4
VMi (g/m2) 117.3  31.1
DV/BSA (mL/m2) 86.3  31.4
SV/BSA (mL/m2) 34.1  25.3
VSDa 50 (24.9)
V dilation 49 (24.4)
eak E wave (cm/s) 0.74  0.2
eak A wave (cm/s) 0.75  0.2
:A ratio 1.04  0.4
Note: Values expressed as mean  standard deviatio
ndividuals with LAV/BSA less than the median value; the
he median value or greater. Tests of significance are t test
Abbreviations and definitions: A wave, late filling velocit
orrected for body surface area; ESV/BSA, end-systolic vo
ndex; LVSD, left ventricular systolic dysfunction.aAssessed using cardiovascular magnetic resonance imaging (haracteristics. Univariate analyses showed that
VSD, LAV/BSA, and history of ischemic heart
isease were significantly associated with death.
idney transplantation was associated with a
ignificant survival benefit. Advancing age in-
reased the risk of death, but this did not reach
tatistical significance. Multivariate analysis
Table 3) was performed and showed LVSD,
AV/BSA, and history of ischemic heart disease
s independent predictors of mortality. Kidney
ransplantation was independently associated with
ecreased mortality.
DISCUSSION
Patients with ESRD have an increased risk of
remature cardiovascular mortality.1 In contrast
o the general population, sudden, presumed ar-
hythmic, cardiac death, rather than myocardial
nfarction or heart failure, is the most common
ause of death.22,23 Modification of traditional
isk factors (eg, dyslipidemia) does not alter
rognosis significantly,24,25 and reversal of LVH
the most common abnormality of uremic cardio-
yopathy) is difficult.6 Alternative, potentially
eversible, myocardial abnormalities have been
ought to provide a target for intervention that
ay decrease cardiovascular death in this patient
opulation.
Against this background, we prospectively
ssessed the effect of additional myocardial
bnormalities and clinical history on survival
hort and by Low or High LAV/BSA
Low LAV/BSA
(n  101)
High LAV
(n  100) P
76.3  26.1 77.4  26.1 0.3
63.4  13.9 62.8  15.0 0.8
115.7  29.8 119.0  32.5 0.4
86.9  30.5 85.8  32.4 0.8
33.7  25.0 34.5  25.7 0.8
23 (22.8) 27 (27) 0.5
23 (22.8) 26 (26) 0.6
0.77  0.2 0.71  0.2 0.3
0.76  0.3 0.72  0.2 0.3
1.06  0.4 1.02  0.4 0.7
number (percentage). The low-LAV/BSA group includes
V/BSA group includes individuals with LAV/BSA equal to
.
ave, early filling velocity; EDV/BSA, end-diastolic volume
orrected for body surface area; LVMi, left ventricular masstire Co
n and
high-LA
and 2
y; E w
lume cejection fraction55%).
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Left Atrial Volume in ESRD Patients With LVH 1093n a cohort of ESRD patients with LVH. In
articular, we investigated the prognostic ef-
ect of LAV, which has been shown previously
sing echocardiography as an independent pre-
ictor of death in dialysis patients.26 LAV can
e calculated reliably from 2-dimensional echo-
ardiography and CMR measurements.14,15 We
estricted this study to patients with LVH to
dentify other potentially modifiable character-
stics that predict death in patients with ESRD
nd established uremic cardiomyopathy.
Figure 2. Kaplan-Meier sur-
ival curves according to (A) left
trial volume (LAV) corrected for
ody surface area (BSA) quar-
iles (Qs; median survival in
ears: Q1, 6.1 1.7; Q2, 5.2
.5; Q3, 4.8  2.6; Q4, 4.6 
.6; log-rank P  0.01) and (B)
resence of left ventricular sys-
olic dysfunction (LVSD; no
VSD group: n  151, mean
urvival 5.4  1.8 years; LVSD
roup: n  50, 4.4  3.9 years;
og-rank P 0.02).
Table 3. Results of Univariate and Multivariate Cox
Variable
Univariate An
HR 95% CI
idney transplantation 0.25 0.12-0.49
schemic heart disease 1.88 1.09-3.23
AV/BSA (per mL/m2) 1.07 1.03-1.12
VSD 1.98 1.12-3.50
jection fraction (per %) 0.98 0.97-1.00
VMi (per g/m2) 1.00 0.99-1.01
eft ventricular dilation 1.48 0.83-2.63
BP (per mm Hg) 1.00 0.98-1.02
BP (per mm Hg) 0.99 0.95-1.03
ge (per y) 1.02 0.99-1.05
SA (m2) 0.28 0.08-1.10
ale sex 0.64 0.37-1.10
RT time (per y) 1.03 0.91-1.18
iabetes mellitus 0.83 0.48-1.41
eart failure 1.08 0.39-2.98
erebrovascular disease 1.97 0.84-4.62
eripheral vascular disease 1.22 0.52-2.84
urrent/ex smokinga 1.56 0.91-2.68
Note: All-cause mortality (n 54) is the dependable varia
Abbreviations and definitions: BSA, body surface area;
ressure; LAV/BSA, left atrial volume corrected for body su
ressure; LVH, left ventricular hypertrophy; LVSD, left ventaNever smoking is the reference category.Elevated LAV (higher than the median) was
ess common in male patients. This differs
rom previous studies that have shown re-
oval of sex-related differences in LAV when
orrected for body size. Neither sex nor BSA
ad an effect on survival in our analyses. There
as no significant difference in cardiovascular
isease history between groups (greater or less
han median LAV). Furthermore, heart rate,
VEF, LVMi, and left ventricle chamber size
at end-diastole and end-systole) were similar
sion Survival Analyses of ESRD Patients With LVH
Multivariate Analyses
P HR 95% CI P
0.001 0.22 0.11-0.43 0.001
0.02 2.73 1.57-4.77 0.001
0.001 1.06 1.02-1.11 0.009
0.02 1.77 1.02-3.15 0.05
0.1
0.6
0.2
0.9
0.8
0.08
0.1
0.1
0.6
0.5
0.9
0.1
0.7
0.1
azard ratio; CI, confidence interval; DBP, diastolic blood
rea; LVMi, left ventricular mass index; SBP, systolic blood
systolic dysfunction; RRT, renal replacement therapy.Regres
alyses
ble.
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Patel et al1094n both groups. This suggests that left atrial
ize was not a marker of reduced diastolic
lling time or impaired left ventricular systolic
mptying.
In the survival analysis, higher LAV was sig-
ificantly associated with poorer survival (Fig
A). Multivariate analysis also showed that in-
reased LAV/BSA and presence of LVSD inde-
endently predicted death in ESRD patients with
VH. As previously demonstrated,17 a clinical
istory of ischemic heart disease was a signifi-
ant independent predictor of death, and kidney
ransplantation was independently associated with
ignificantly improved survival.27
These data confirm previous studies investigat-
ng LAV and survival.26 However, in previous
tudies no analyses were performed in patients
ith pre-existing myocardial abnormalities. We
elieve that the strength of this study lies with
ccurate assessment of LVMi using CMR imag-
ng, which provides an accurate, volume-indepen-
ent, and reproducible method of measuring
VM.9
In the present study, LAV was not significantly
orrelated with LVM, suggesting that increased
AV is not caused solely by impaired atrial
mptying into a large, poorly compliant, left
entricle. In other patient populations, increased
AVs are considered to reflect the long-term
ffects of increased ventricular filling pres-
ures.28 Thus, when filling pressures are in-
reased, the atria (like the ventricles) will enlarge
n response to pressure and chronic volume over-
oad.29 LAV was not associated with diastolic
ysfunction in our population as measured using
:A ratio. We did not obtain tissue Doppler or
ulmonary venous blood flow velocity data to
ully evaluate diastolic function, and it is likely
hat diastolic dysfunction is common in ESRD
atients with LVH. Thus, we postulate that in
SRD patients with LVH, left atrial enlargement
s caused largely by diastolic dysfunction and
lso chronic fluid overload due to expansion in
ntravascular volume.
A decrease in LAV has been achieved in pa-
ients with mitral valve disease and atrial fibrilla-
ion30,31; however, its effect on overall prognosis
s unknown. Whether tight control of fluid vol-
me status in patients with ESRD similarly de-
reases LAV and mortality will require a con-
rolled clinical trial. nWe have previously shown that LVSD is asso-
iated with (often asymptomatic) ischemic heart
isease and, in turn, poorer survival.4 This pre-
umably is caused by occlusive large-vessel dis-
ase and inadequate growth of penetrating epicar-
ial vessels in response to cardiac myocyte
ypertrophy. Ventricular action potential propa-
ation and recovery are impaired in the presence
f LVH and LVSD, increasing the risk of ventric-
lar re-entrant tachyarrhythmias.32,33 The prog-
ostic benefits of improving systolic function of
SRD patients, using pharmacological ap-
roaches or modification of dialysis remain to be
ssessed.
In contrast to previous studies using echocardi-
graphy to assess left ventricular dimensions,34
igher LVMi was not a significant predictor of
ortality in this cohort of patients. We have
reviously shown inaccuracies of echocardiogra-
hy measurements in patients with ESRD,35 and
t is likely that the use of CMR imaging to
ccurately assess myocardial mass will provide
ore reliable prognostic information in the fu-
ure.
We accept that this study has some limitations.
atients recruited to this study were being as-
essed for kidney transplantation and may not be
epresentative of all patients with ESRD. How-
ver, since these patients were considered healthy
nough to be considered for a kidney transplant,
e believe these results would be relevant to
ther patients with more significant comorbid
onditions. In addition, we obtained limited infor-
ation regarding ventricular diastolic function
n our cohort and hopefully, as more detailed
ethods (eg, tissue Doppler) are utilized, these
ata will become available.
In conclusion, in ESRD patients with LVH,
ncreased LAV and the presence of LVSD are
ndependent predictors of death and may provide
ovel factors that may be amenable to modification
o improve cardiovascular prognosis.
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